Dr. Blain is an internationally known expert in cell cycle and cancer biology and is one of the world’s experts on p27Kip1. She has been studying cell cycle regulation for more than 25 years as an NIH funded investigator and a tenured Associate Professor at the SUNY Downstate Medical Center. She founded Concarlo Therapeutics, capitalizing on discoveries she made and patented, and became its CEO in 2023. Concarlo is focused on the potential of p27 targeting and its unique ability to inhibit the three main drivers of cancer progression and drug resistance, CDK4/6 and CDK2. Dr. Blain was trained at Princeton University, Columbia University and the Memorial Sloan-Kettering Cancer Center.
Stacy Blain
